For example, the detection of a secondary mutation in the epidermal growth factor receptor (EGFR) gene in lung cancer patients who initially responded to EGFR inhibitors but then relapsed can guide the switch to alternative therapies designed to overcome resistance (Kulda et al., 2023; Rotow et al., 2024). This evidence concerns the gene EGFR and lung carcinoma.